Novartis says lung cancer drug canakinumab failed phase III trial

Article content

ZURICH — Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial.

The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said. (Reporting by John Revill; Editing by Christian Schmollinger)